CoChat

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

Open access
De Moraes, C. Gustavo, Liebmann, Jeffrey M., Levin, Leonard A. · 2017 · Progress in Retinal and Eye Research
Cited by 203

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP‐lowering therapies, it is expected that effects on IOP will translate into benefits in long‐term patient‐reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12–18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health‐related quality of life, as defined by validated instruments designed to measure that endpoint. HIGHLIGHTSA 30% decrease in rate of visual field progression can be projected to have a significant effect on health‐related quality of life.The US FDA definition of clinically‐meaningful progression corresponds to a slope ≤−0.5 dB/yr in ≥5 abnormal test locations.A 30% decrease in visual field progression with trend analysis is equivalent to a 2–3 mmHg decrease in intraocular pressure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.preteyeres.2016.10.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 203

Metadata

Authors
De Moraes, C. G., Liebmann, J. M., & Levin, L. A.
Venue
Progress in Retinal and Eye Research
Publisher
Elsevier BV
Published
2017-01
Volume
56
Pages
107-147
ISSN
1350-9462 (ISSN-L)
OpenAlex
W2538869024
Cited by
203
References
2
FWCI
10.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. https://app.cochat.ai/papers/10.1016/j.preteyeres.2016.10.001
The paper
De Moraes, C. G., Liebmann, J. M., & Levin, L. A. (2017). Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2016.10.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.